| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.097 | 0.008 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.009 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.091 | 0.009 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.009 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.01 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | 0.12 | 0.01 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |